Rituximab Transplant denied as not medically necessary by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for rituximab transplant are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denies Rituximab (Transplant Context) on Medical-Necessity Grounds

Blue Cross Blue Shield plans commonly deny rituximab in transplant-related indications — such as desensitization protocols, antibody-mediated rejection treatment, or post-transplant lymphoproliferative management — when the submitted documentation does not clearly tie the request to a recognized clinical protocol and demonstrate that standard alternatives have been considered or are inappropriate. Because transplant medicine is a specialized field with evolving evidence, BCBS medical directors often apply a narrow read of their internal coverage criteria and will deny when the clinical rationale is not spelled out explicitly.

This denial is absolutely worth challenging. Rituximab has well-established roles in transplant medicine recognized by leading transplant societies, and a denial based on medical necessity is a reviewable determination — not a final word.

## Your Appeal Rights

Under ACA Section 2719, non-grandfathered individual and group plans must offer internal appeal and independent external review. Under ERISA Section 503, employer-sponsored plans must provide a full-and-fair review. You typically have up to 180 days from the denial date to file an internal appeal. If the internal appeal fails, you may request independent external review — in most states, this must be initiated within four months of the final internal denial. If the clinical situation is urgent, you are entitled to request expedited review, which compresses timelines to days rather than weeks.

## Building a Strong Medical-Necessity Appeal

The goal is to show BCBS — and, if needed, an independent reviewer — that rituximab is the medically necessary and appropriate treatment for this specific patient at this specific stage of care.

Documentation to assemble: - Transplant history: organ type, date of transplant, current immunosuppression regimen, and relevant labs (ask your transplant team for the chart summary) - Diagnosis confirmation: the specific indication being treated (e.g., antibody-mediated rejection, sensitization status, PTLD diagnosis), confirmed in writing by the treating transplant physician - Prior treatment record: what therapies have been attempted, in what sequence, with dates and documented outcomes or adverse effects - Clinical severity documentation: current functional status, organ function trend, and any urgency factors that make delay harmful - Prescriber medical-necessity letter: a detailed letter from the transplant physician explaining why rituximab is indicated for this patient, why alternatives are insufficient, and how this aligns with recognized transplant medicine guidelines

## Criteria-Mapping Structure

Obtain two documents before writing your appeal narrative: 1. The FDA-approved prescribing information for rituximab — this defines labeled and recognized uses. 2. BCBS's published medical policy for rituximab in transplant indications — request this by name from BCBS or locate it on their provider policy portal.

For each criterion listed in the BCBS policy, create a line-by-line response: - Policy requires: [copy the exact requirement verbatim] - Patient record shows: [cite the specific chart note, date, and finding that satisfies it]

This structure forces the reviewer to address each point individually and makes it difficult to issue a blanket denial on the appeal.